Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Cipla collaboration brings a second brand of tirzepatide, Yurpeak, to India, aiming to widen patient access for diabetes and ...

Cipla will market Eli Lilly’s diabetes and weight-loss drug Mounjaro as Yurpeak in India, enhancing accessibility and ...

Stay up-to-date with the Cipla Stock Liveblog, your comprehensive source for real-time updates and detailed analysis on a ...

Analysts say that while the deal is a positive for the stock, it has already been priced in and investors are now resorting ...

The Zepbound vials will be offered for pick-up at Walmart pharmacies across the U.S. starting in mid-November at LillyDirect's direct-to-consumer pricing which offers the drug at half the price ...

Eli Lilly's launch of Mounjaro in India in March 2025 was the first step of Tirzepatide in the country. In June 2025, the ...

Side effects: Like semaglutide, tirzepatide’s most common side effects are nausea, diarrhea, vomiting, stomach pain, and ...

The availability of compounded GLP-1 drugs shifted after the FDA changed their regulations in April 2025. Here’s what to know.

Say local manufacturing improves convenience of long-term therapy, stabilises supply chains and lowers prices.

The MHRA's raid follows an uptick in the trade of illegal GLP-1RA drugs used for obesity and type 2 diabetes amid shortages ...

October 30th is the day when Eli Lilly will report its third-quarter results, including sales of its 'superstars' Zepbound ...